Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Its lead candidates are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. The company was founded on June 5, 1987 and is headquartered in Monmouth Junction, NJ.
Sector:
Commercial Services
Industry:
Miscellaneous Commercial Services
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Advaxis, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Advaxis, Inc. market cap is $1.42M.
What is the 52-week high for Advaxis, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Advaxis, Inc. 52 week high is $0.801 as of October 10, 2025.
What is the 52-week low for Advaxis, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Advaxis, Inc. 52 week low is $0.026 as of October 10, 2025.
What is Advaxis, Inc. stock price today?
Advaxis, Inc. stock price today is $1.31.
What was Advaxis, Inc. stock price yesterday?
Advaxis, Inc. stock price yesterday was $0.5899.
What is the 50-day moving average of Advaxis, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Advaxis, Inc. 50-day moving average is $0.054.